RCT of Vinehealth® digital health cancer solution

  • Research type

    Research Study

  • Full title

    Multi-centre, randomised controlled trial of Vinehealth® digital health cancer solution for cancer patients commencing chemotherapy

  • IRAS ID

    300753

  • Contact name

    Agnieszka Michael

  • Contact email

    a.michael@surrey.ac.uk

  • Sponsor organisation

    University of Surrey

  • ISRCTN Number

    ISRCTN44293246

  • Duration of Study in the UK

    0 years, 11 months, 31 days

  • Research summary

    Global cancer deaths are projected to increase 45% by 2030. Rising survival means many patients remain on long-term toxic treatments for \>10 years, so improving Quality of Life (QoL) for cancer patients is crucial. This presents an urgent and growing need for personalised tools to support cancer patient self-management and data collection to enable monitoring and remote follow-up.

    Currently, patient information and support is dispersed, inaccessible and poorly personalised.Majority of patients receive a written information and a brief session with a doctor or a specialised nurse to explain the side effects of chemotherapy and the schedule of treatment . The management of side effects varies between the care providers with some hospitals offering access to 24hr chemotherapy hotline and other hospitals providing only 9-5 hrs advice. Macmillan's Cancer Patient Experience Survey (2020) reported 39% patients stated treatment side-effects were not explained in a way they could understand. 44% were not offered individual information and support in dealing with side-effects. Macmillan report that GPs are not able to take on this care, given workforce pressures.

    Vinehealth® is a highly innovative solution meeting these unmet needs. Vinehealth®'s digital platform combines behavioural science and AI to improve cancer patient experience, care delivery and clinical outcomes. Vinehealth®'s patient-facing mobile app collates information from partners across the cancer ecosystem, deploying Machine Learning (ML)-driven personalised support to enable better self-management of medications, side-effects, symptoms and lifestyles, seamlessly integrating with smartphones and wearables.

    The project objectives are to undertake sufficiently large Randomised Clinical Trial (RCT) to provide robust evaluation of claims that Vinehealth®'s platform can effectively: 1. Collect Patient Reported Outcomes (PRO) data in clinical studies 2. Improve patient self-management 3. Reduce emergency healthcare utilisation.

  • REC name

    East of Scotland Research Ethics Service REC 2

  • REC reference

    22/ES/0007

  • Date of REC Opinion

    16 Mar 2022

  • REC opinion

    Further Information Favourable Opinion